Literature Highlights - July 2024

Daily oral upadacitinib 30 mg and ABBV-599 high dose (elsubrutinib 60 mg QD + upadacitinib 30 mg) were effective in multiple outcome measures including disease activity, flares, time to first flare, and joint counts.

more…

Keywords:

Upadacitinib, Elsubrutinib, Efficacy, Safety, LLDAS